Eli Lilly announced it will acquire Merida Biosciences in a deal valued at up to about $2.88 billion, adding a precision immunology platform focused on eliminating pathogenic autoantibodies while preserving the rest of the immune system. The acquisition centers on Merida’s lead Fc therapeutic, MER511, currently in Phase 1 for Graves’ disease and thyroid eye disease. Lilly said MER511 is designed to bind disease-driving thyroid-stimulating antibodies and route them to degradation pathways, targeting the underlying autoantibody biology rather than broad immune suppression. The companies positioned the mechanism as potentially scalable across antibody-driven diseases. The deal extends Lilly’s 2026 acquisition pace and broadens its immune pipeline beyond obesity-driven revenue dynamics. For investors, the Merida transaction is a continuation of a strategy shift toward immunology precision and targeted control of disease-relevant immune components. In competitive terms, the acquisition intensifies the race for antibody-directed therapies in endocrine autoimmunity, where durable efficacy and safety—especially around immune-system preservation—are central to differentiation.